← All trials
NCT05629468
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Aug 31, 2022
- First posted
- Nov 29, 2022
- Last posted
- Dec 5, 2022
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of PakistanLead sponsor
- Government of PakistanReponsible party - principal investigator
- Riphah International UniversityOfficial
- Government of PakistanSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.